FOI release

New patient starts by month for certain breast cancer medicines

Case reference FOI2026/00538

Received 22 February 2026

Published 18 March 2026

Request

Dear Oxford Universtiy Hospitals Please can you kindly confirm in writing:

1. The number of new patient initiations per month with trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [NICE TA458] – covering Sep 24 to Jan 2026 (inclusive)

2. The number of new patient initiations with tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [NICE TA786], by month, between Sep 24 and Jan 26

Response

1. The number of new patient initiations per month with trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [NICE TA458] - covering Sep 24 to Jan 2026 (inclusive): 28

2. The number of new patient initiations with tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [NICE TA786], by month, between Sep 24 and Jan 26: 15

Documents

There are no documents for this release.

This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.